TY - T1的认知能力之间的关系和新确诊癫痫病灶患者主观症状(S21.003) JF -神经学乔-神经学六世- 88 - 16补充SP - S21.003盟Kimford tommeador一路盟Andres Kanner AU -克里斯Morrision盟Adrian Schembri首页 AU -戴尔Hesdorffer盟特伦斯O ' brien AU -帕特丽夏Penovich盟-迈克尔·斯珀林AU -大卫·达比非盟-凯文·麦肯纳盟旋律Winawer AU -塞布丽娜Cristofaro Y1 - 2017/04/18 UR - //www.ez-admanager.com/content/88/16_Supplement/S21.003.abstract N2 -目的:证明客观认知表现和主观症状之间的关系/观念在新确诊癫痫灶。背景:人类癫痫计划(玫瑰)是一个前瞻性观察研究试图确定临床特点和生物标记物预测疾病的治疗反应,在新确诊癫痫病灶进展和结果。作为调查的一部分,神经心理学数据收集来决定如果他们预测治疗效果,并描绘不良认知/行为抗癫痫药物治疗的效果和持续的癫痫发作。在这里,我们检查神经心理措施之间的关系和主观经验(症状和认知)在注册新诊断的患者,并且假定客观/主观措施将不相关的。设计/方法:患者进入消息灵通的研究经历了认知测试Cogstate(在线计算机测试电池评估函数像注意,内存,和处理速度),这是敏感的疾病和药物的影响。消息灵通的参与者在完成测试后登记和期间每三个月之后他们的参与。认知任务包括:检测(检波器),识别(IDN),一个回内存(ONB),一个卡片学习(OCL),格罗顿迷宫学习(GML)。结果变量速度检波器,印度尼西亚和ONB;OCL的准确性;对GML和总错误。主观的措施包括:癫痫患者的生活质量10-patient (QOLIE-10p),神经障碍抑郁量表对癫痫(NDDI-E)流行病学中心Studies-Depression(鉴定),AB神经心理评估量表(ABNAS)和不良事件(AEP)。皮尔逊相关性评估措施登记。结果:304名患者。 Significant correlations were present between all subjective measures (r=− .706 to .761). Each Cogstate measure was related to 1–3 other Cogstate measures (r=−.307 to .578). Only two significant correlations existed between subjective and cognitive measures (QOLIE-10p to ONB, r=−.175 and CES-D to OCL, r=−.166).Conclusions: Subjective experiences (i.e., QOL, mood, side effects) and cognitive performance measures display little relation to each other in this cohort with newly diagnosed focal epilepsy.Study Supported by: The Epilepsy Study Consortium (ESCI) is a non-profit organization dedicated to accelerating the development of new therapies in epilepsy to improve patient care. The funding provided to ESCI to support HEP comes from industry, philanthropy and foundations (Eisai, Lundbeck, Pfizer, Sunovion, UCB Pharma, Finding A Cure for Epilepsy and Seizures, The Andrews Foundation, Friends of Faces, and others).Disclosure: Dr. Meador has received personal compensation for activities with the Epilepsy Study Consortium as a consultant. Dr. Meador has received research support from Sunovion. Dr. Kanner has received personal compensation for activities with Medscape. Dr. Morrision has nothing to disclose. Dr. Schembri has received personal compensation for activities with Cogstate as an employee. Dr. Hesdorffer has received personal compensation for activities with Cyberonics, Mount Sinai Injury Prevention Center, and Upsher Smith. Dr. Hesdorffer has received personal compensation in an editorial capacity for Epilepsia. Dr. Hesdorffer has received research support from the Epilepsy Study Consortium. Dr. O'Brien has received personal compensation for activities with UCB Pharma and Eisai Inc. Dr. O'Brien has received research support from Eisai Inc., UCB Pharma, Sanofi-Aventis Pharmaceuticals, Inc., SciGen, Marinus and UPS. Dr. Penovich has received personal compensation for activities with Lundbeck, Sunovion and UCB, Inc. as a member of the speaker's bureau. Dr. Sperling has received personal compensation for activities with Medscape and Medtronic as a consultant. Dr. Sperling has received research support from UCB Pharma, Eisai, Sunovion, GlaxoSmithKline, SK Life Science, Upsher Smith, Neurelis, Accorda, Medtronic, and Brain Sentinel. Dr. Darby has received personal compensation for activities with CogState. Dr. McKenna has nothing to disclose. Dr. Winawer has nothing to disclose. Dr. Cristofaro has nothing to disclose. ER -